12:00 AM
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Macitentan: Phase I started

Actelion disclosed in its 4Q11 earnings that it began an open-label, U.S. Phase I trial to evaluate oral macitentan given daily in combination with 150 mg/m 2 temozolomide every other week for 12 months in 48 patients. In the first part of...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >